Company Overview

Ampio Pharmaceuticals, Inc. was a U.S.-based biopharmaceutical company focused on developing immunomodulatory and anti-inflammatory therapies for inflammatory conditions and respiratory diseases. The company historically operated in the biotechnology and specialty pharmaceutical sectors, with research efforts centered on compounds intended to reduce inflammation while limiting side effects commonly associated with corticosteroids and other systemic therapies. Its primary development candidate was Ampion, a biologic derived from human serum albumin that was investigated primarily for osteoarthritis of the knee and certain inflammatory indications.

The company’s business model relied largely on clinical-stage drug development rather than commercialized product sales, meaning its historical revenue base was primarily tied to financing activities rather than recurring pharmaceutical product revenue. Ampio positioned itself around the potential therapeutic application of low-molecular-weight fractions derived from albumin-based compounds and sought differentiation through anti-inflammatory mechanisms that it claimed could address unmet medical needs in musculoskeletal and pulmonary disease categories. Public filings and market disclosures indicate the company experienced substantial operational and financial challenges following mixed clinical outcomes and regulatory setbacks. Data regarding ongoing active operations after its restructuring and market delisting is inconclusive based on available public sources.

Business Operations

Ampio Pharmaceuticals historically operated as a single-segment biotechnology company focused on drug research, clinical development, and regulatory advancement activities. Its principal asset was Ampion, which underwent multiple clinical studies for osteoarthritis of the knee and was also explored in inflammatory and respiratory applications. The company conducted development activities primarily in the United States and relied on outsourced manufacturing, contract research organizations, and clinical trial partners rather than maintaining large-scale commercial manufacturing infrastructure.

The company’s operations included intellectual property management, clinical trial administration, regulatory submissions, and capital raising activities common to development-stage biotechnology firms. Public disclosures referenced collaborations with clinical research providers and external manufacturing organizations, although no large-scale long-term strategic joint venture or global commercialization partnership was consistently identified in verified filings. Ampio’s operational footprint remained relatively limited internationally, with most identifiable activities concentrated in U.S.-based development and corporate administration functions.

Strategic Position & Investments

Ampio Pharmaceuticals pursued a strategy centered on advancing anti-inflammatory biologic candidates through late-stage clinical development and eventual regulatory approval. The company invested heavily in clinical studies evaluating Ampion for osteoarthritis-related pain and inflammation, seeking positioning within the broader musculoskeletal therapeutics market. It also explored potential applications in pulmonary inflammation and immune-related conditions during periods of heightened interest in respiratory therapeutics.

Publicly available filings indicate the company’s strategic direction shifted over time toward cost containment, restructuring, and preservation of remaining assets after clinical and regulatory difficulties affected its development timeline and financing position. No major transformative acquisition activity was consistently documented in verified public filings. Information regarding active portfolio subsidiaries, material venture investments, or sustained commercial-stage diversification is limited, and data on continuing strategic operations after restructuring actions is inconclusive based on available public sources.

Geographic Footprint

Ampio Pharmaceuticals was headquartered in Colorado, United States, and its operational activities were concentrated primarily within the U.S. biotechnology market. Clinical development efforts, investor relations activities, and regulatory interactions were largely tied to U.S.-based institutions, including oversight involving the U.S. Food and Drug Administration.

The company did not maintain a broad multinational commercial footprint comparable to large pharmaceutical manufacturers. While certain clinical activities and external vendor relationships may have involved international participants, publicly available information indicates the company’s principal operational influence remained centered in North America. Evidence of significant direct market penetration across Europe, Asia-Pacific, or Latin America was limited in available public disclosures.

Leadership & Governance

Ampio Pharmaceuticals was founded by Richard Giles, who was associated with the company’s early scientific and strategic development efforts. During its later operating years, leadership focused heavily on advancing clinical programs, managing financing requirements, and responding to regulatory developments affecting the company’s primary drug candidate pipeline. Public communications and filings reflected a governance emphasis on clinical execution, capital management, and efforts to achieve regulatory milestones.

Key executives and leadership figures identified in public filings and corporate disclosures included:

• Michael Macaluso – Chief Executive Officer
• Richard Giles – Founder and former executive leadership figure
• David Bar-Or, MD – Chief Scientific Officer
• Todd Hart – Chief Financial Officer

Leadership composition changed over time as the company underwent restructuring and operational transitions. Certain executive roles and board memberships varied across reporting periods, and some governance information following the company’s later-stage restructuring activity is inconclusive based on available public sources.